Miransertib Uses, Dosage, Side Effects and more
Miransertib is under investigation in clinical trial NCT01473095 (Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma).
| Trade Name | Miransertib |
| Generic | Miransertib |
| Miransertib Other Names | Miransertib |
| Type | |
| Formula | C27H24N6 |
| Weight | Average: 432.531 Monoisotopic: 432.206244797 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
